Abstract Library

#2235 Efficacy of Sunitinib Correlated with Clinical, Radiological Variables, Dose-Intensity and Treatment Time in Advanced Grade 1-2 Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study NCT02841865)

Introduction: Sunitinib has been shown to be effective in advanced pancreatic neuroendocrine tumors (PNETs) but it is not well known how dose-intensity and treatment time influence the results.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Jimenez-Fonseca P, Solis Hernandez M, Fernandez del Valle A, Garcia-Carbonero R, Matos I,

Keywords: PNET, sunitinib, dose-intensive, progression-free survival,

#2217 Prognostic Impact of CHOI Response Criteria Compared to RECIST in Grade 1-2 Advanced Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study-NCT02841865)

Introduction: Response Evaluation Criteria In Solid Tumors (RECIST) are not presumably the most optimal option for predicting the benefit of antiangiogenic drugs in neuroendocrine tumors (NETs), given that tumor shrinkage is not frequent, and qualitative changes in tumor tissues are to be expected.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Carmona-Bayonas A, Fernandez del Valle A, Solis M, Matos I, Garcia-Carbonero R,

Keywords: CHOI criteria, pancreatic neuroendocrine tumor, RECIST, response, survival,

#2209 The ENETS Registry: First Results of a Collaborative Effort Including over 12.000 Patients with Neuroendocrine Neoplasms (NENs) from 7 European Countries

Introduction: NENs are rare and global European epidemiologic data are only based on national or compilation of national registries. So, there is a need for comprehensive homogenous information

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Borbath I

Authors: Borbath I, Pape U, Garcia-Carbonero R, Sedláčková E, Kollár A,

Keywords: ENETS registry, Europe,

#1937 Clinical Features and Outcomes of Advanced PNETs Treated with Sunitinib: Data from CRIPNET-GETNE Study

Introduction: There are several effective drugs for advanced pancreatic neuroendocrine tumors (PNETs) but the right treatment sequence hasn’t been defined yet.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Solis-Hernandez M

Authors: Solis-Hernandez M, Calvo-Temprano D, Carmona-Bayonas A, García-Carbonero R, Custodio A,

Keywords: Sunitinib, targeted therapies,

#1772 Expression of Truncated Functional Subtype 5 Somatostatin Receptor Variant (sst5TMD4) in GEP-NETs and Association with Relevant Pathways Involved in NET Tumorigenesis

Introduction: Sst5TMD4, which is derived from a non-canonical splicing process of sst5 receptor, is overexpressed in several endocrine tumors and associated with a worse prognosis.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Diaz Perez A, Martínez-Fuentes A, García-Carbonero R, Luque R, Jimenez-Fonseca P,

Keywords: somatostatin receptor, neuroendocrine tumors,